BlackRock Investment Management’s PTC Therapeutics PTCT Stock Holding History

BlackRock Investment Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.77M	Sell	162,274 -19,197	-11%	-$201K	﹤0.01%	2299
2016 Q3	$2.54M	Sell	181,471 -1,846	-1%	-$15K	﹤0.01%	1958
2016 Q2	$1.29M	Buy	183,317 +26,361	+17%	+$193K	﹤0.01%	2441
2016 Q1	$1.01M	Buy	156,956 +18,710	+14%	+$325K	﹤0.01%	2487
2015 Q4	$4.48M	Buy	138,246 +1,558	+1%	+$45.9K	0.01%	1466
2015 Q3	$3.65M	Sell	136,688 -2,458	-2%	-$105K	﹤0.01%	1602
2015 Q2	$6.7M	Buy	139,146 +43,228	+45%	+$2.52M	0.01%	1272
2015 Q1	$5.84M	Buy	95,918 +5,590	+6%	+$341K	0.01%	1265
2014 Q4	$4.68M	Buy	90,328 +24,842	+38%	+$1.09M	0.01%	1408
2014 Q3	$2.88M	Buy	65,486 +585	+0.9%	+$18.3K	﹤0.01%	1735
2014 Q2	$1.7M	Buy	64,901 +32,439	+100%	+$694K	﹤0.01%	2212
2014 Q1	$849K	Buy	32,462 +5,131	+19%	+$138K	﹤0.01%	2635
2013 Q4	$464K	Buy	27,331 +1,006	+4%	+$17.7K	﹤0.01%	2986
2013 Q3	$565K	Buy	+26,325	New	+$457K	﹤0.01%	2850

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

BlackRock Investment Management's PTCT Position: Q4 2016 in Review

BlackRock Investment Management reduced its PTC Therapeutics (PTCT) stake by 11% in Q4 2016, selling an estimated $201K and leaving 162,274 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2299.

BlackRock Investment Management first reported a position in PTCT in Q3 2013 and has held it in 14 quarters since. The position peaked at $6.7M in Q2 2015. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

BlackRock Investment Management held 162,274 shares of PTC Therapeutics worth $1.77M as of Q4 2016.
BlackRock Investment Management sold 19,197 PTC Therapeutics shares in Q4 2016, an estimated $201K.
PTC Therapeutics made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #2299 holding.
BlackRock Investment Management first reported a position in PTC Therapeutics in Q3 2013 and has held it in 14 quarters since.
BlackRock Investment Management's PTC Therapeutics position peaked at $6.7M in Q2 2015.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.